• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

溶瘤腺病毒编码的RNAi分子以前体pri-miRNA形式表达时最为有效。

Expression of Oncolytic Adenovirus-Encoded RNAi Molecules Is Most Effective in a pri-miRNA Precursor Format.

作者信息

Brachtlova Tereza, van Ginkel Jan-Willem, Luinenburg Mark J, de Menezes Renée X, Koppers-Lalic Danijela, Pegtel D Michiel, Dong Wenliang, de Gruijl Tanja D, van Beusechem Victor W

机构信息

Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam Infection & Immunity Institute, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.

ORCA Therapeutics B.V., 1081 HV Amsterdam, the Netherlands.

出版信息

Mol Ther Oncolytics. 2020 Oct 27;19:332-343. doi: 10.1016/j.omto.2020.10.012. eCollection 2020 Dec 16.

DOI:10.1016/j.omto.2020.10.012
PMID:33335978
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7723779/
Abstract

Oncolytic adenoviruses are being developed as new anti-cancer agents. Their efficacy can be improved by incorporating RNA interference (RNAi) molecules. RNAi molecules can be expressed in various precursor formats. The aim of this study was to determine the most effective format. To this end, we constructed three Δ24-type oncolytic adenoviruses, with human microRNA-1 (miR-1) expression cassettes in short hairpin RNA (shRNA), precursor microRNA (pre-miRNA), and primary miRNA (pri-miRNA) format, respectively. The viruses were compared for virus replication, mature miR-1 expression, and target gene silencing in cancer cells. Incorporation of the cassettes had only minor effects on virus replication. Mature miR-1 expression from the pri-miRNA format reached on average 100-fold higher levels than from the other two formats. This expression remained stable upon long-term virus propagation. Infection with the pri-miR-1-expressing virus silenced the validated miR-1 targets FOXP1 and MET. knockout almost completely abrogated mature miR-1 expression, confirming that processing of adenovirus-encoded pri-miR-1 was dependent on the host cell miRNA machinery. Using simple recombination cloning, a similar virus expressing miR-26b was made and shown to silence the validated miR-26b target PTGS2. We thus provide a platform for construction of oncolytic adenoviruses with high expression of RNAi molecules of choice.

摘要

溶瘤腺病毒正被开发为新型抗癌药物。通过整合RNA干扰(RNAi)分子可提高其疗效。RNAi分子可以多种前体形式表达。本研究的目的是确定最有效的形式。为此,我们构建了三种Δ24型溶瘤腺病毒,分别带有短发夹RNA(shRNA)、前体微小RNA(pre-miRNA)和初级微小RNA(pri-miRNA)形式的人微小RNA-1(miR-1)表达盒。比较了这些病毒在癌细胞中的病毒复制、成熟miR-1表达和靶基因沉默情况。表达盒的整合对病毒复制只有轻微影响。pri-miRNA形式的成熟miR-1表达平均比其他两种形式高100倍。在长期病毒传代过程中,这种表达保持稳定。用表达pri-miR-1的病毒感染可使已验证的miR-1靶标FOXP1和MET沉默。敲除几乎完全消除了成熟miR-1表达,证实腺病毒编码的pri-miR-1的加工依赖于宿主细胞的miRNA机制。通过简单的重组克隆,制备了一种表达miR-26b的类似病毒,并证明其可使已验证的miR-26b靶标PTGS2沉默。因此,我们提供了一个构建可高表达所选RNAi分子的溶瘤腺病毒的平台。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b4a/7723779/d516ffdaa6b2/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b4a/7723779/18e10371b263/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b4a/7723779/d571694e2f3c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b4a/7723779/7662dba023a2/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b4a/7723779/91deca433f5e/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b4a/7723779/b6a5824c3948/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b4a/7723779/d516ffdaa6b2/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b4a/7723779/18e10371b263/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b4a/7723779/d571694e2f3c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b4a/7723779/7662dba023a2/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b4a/7723779/91deca433f5e/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b4a/7723779/b6a5824c3948/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b4a/7723779/d516ffdaa6b2/gr5.jpg

相似文献

1
Expression of Oncolytic Adenovirus-Encoded RNAi Molecules Is Most Effective in a pri-miRNA Precursor Format.溶瘤腺病毒编码的RNAi分子以前体pri-miRNA形式表达时最为有效。
Mol Ther Oncolytics. 2020 Oct 27;19:332-343. doi: 10.1016/j.omto.2020.10.012. eCollection 2020 Dec 16.
2
Functional Screening Identifies Human miRNAs that Modulate Adenovirus Propagation in Prostate Cancer Cells.功能筛选鉴定出调节前列腺癌细胞中腺病毒增殖的人类 miRNA。
Hum Gene Ther. 2017 Sep;28(9):766-780. doi: 10.1089/hum.2016.143. Epub 2017 Jan 23.
3
Expressed anti-HBV primary microRNA shuttles inhibit viral replication efficiently in vitro and in vivo.表达的抗乙肝病毒初级微小RNA穿梭体在体外和体内均能有效抑制病毒复制。
Mol Ther. 2008 Jun;16(6):1105-12. doi: 10.1038/mt.2008.82. Epub 2008 Apr 22.
4
Adenovirus VA RNAs impair maturation of primary microRNA.腺病毒 VA RNAs 损害初级 microRNA 的成熟。
J Gene Med. 2023 Dec;25(12):e3564. doi: 10.1002/jgm.3564. Epub 2023 Jul 11.
5
Successful disabling of the 5' UTR of HCV using adeno-associated viral vectors to deliver modular multimeric primary microRNA mimics.使用腺相关病毒载体递送模块化多聚体初级微小RNA模拟物成功抑制丙型肝炎病毒的5'非翻译区。
J Virol Methods. 2016 Sep;235:26-33. doi: 10.1016/j.jviromet.2016.05.008. Epub 2016 May 12.
6
Oncolytic Measles Virus Encoding MicroRNA for Targeted RNA Interference.溶瘤麻疹病毒编码 microRNA 用于靶向 RNA 干扰。
Viruses. 2023 Jan 22;15(2):308. doi: 10.3390/v15020308.
7
Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles.利用包含微小RNA穿梭载体的模块化三聚体Pol II表达盒实现基因表达的高效沉默。
Nucleic Acids Res. 2009 Jul;37(13):e91. doi: 10.1093/nar/gkp446. Epub 2009 May 27.
8
MicroRNA miR-27 Inhibits Adenovirus Infection by Suppressing the Expression of SNAP25 and TXN2.微小RNA miR-27通过抑制SNAP25和TXN2的表达来抑制腺病毒感染。
J Virol. 2017 May 26;91(12). doi: 10.1128/JVI.00159-17. Print 2017 Jun 15.
9
Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease.在晚期非酒精性脂肪性肝病中,microRNA 加工酶的基因表达发生改变。
J Gastroenterol Hepatol. 2013 Aug;28(8):1410-5. doi: 10.1111/jgh.12268.
10
Generating DNA Expression Cassettes Encoding Multimeric Artificial MicroRNA Precursors.生成编码多聚体人工 microRNA 前体的 DNA 表达盒。
Methods Mol Biol. 2020;2115:185-197. doi: 10.1007/978-1-0716-0290-4_11.

引用本文的文献

1
Overview of host-directed antiviral targets for future research and drug development.未来研究和药物开发的宿主导向抗病毒靶点概述。
Acta Pharm Sin B. 2025 Apr;15(4):1723-1751. doi: 10.1016/j.apsb.2025.03.011. Epub 2025 Mar 8.
2
miRNA-Mediated Mechanisms in the Generation of Effective and Safe Oncolytic Viruses.微小RNA介导的有效且安全的溶瘤病毒产生机制
Pharmaceutics. 2024 Jul 25;16(8):986. doi: 10.3390/pharmaceutics16080986.
3
Quantitative Virus-Associated RNA Detection to Monitor Oncolytic Adenovirus Replication.定量病毒相关 RNA 检测监测溶瘤腺病毒复制。

本文引用的文献

1
A simplified system for the effective expression and delivery of functional mature microRNAs in mammalian cells.一种用于在哺乳动物细胞中有效表达和递呈功能成熟 microRNA 的简化系统。
Cancer Gene Ther. 2020 Jun;27(6):424-437. doi: 10.1038/s41417-019-0113-y. Epub 2019 Jun 20.
2
Unleashing the Full Potential of Oncolytic Adenoviruses against Cancer by Applying RNA Interference: The Force Awakens.通过应用RNA干扰释放溶瘤腺病毒对抗癌症的全部潜能:原力觉醒。
Cells. 2018 Nov 23;7(12):228. doi: 10.3390/cells7120228.
3
Bioselection Reveals miR-99b and miR-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer.
Int J Mol Sci. 2024 Jun 14;25(12):6551. doi: 10.3390/ijms25126551.
4
RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment.RCAd-LTH-shPD-L1,一种具有增强抗肿瘤免疫的双基因重组溶瘤腺病毒,增加了淋巴细胞浸润并重塑了肿瘤微环境。
J Immunother Cancer. 2024 Jan 11;12(1):e007171. doi: 10.1136/jitc-2023-007171.
5
Remodeling the tumor immune microenvironment with oncolytic viruses expressing miRNAs.利用表达 miRNA 的溶瘤病毒重塑肿瘤免疫微环境。
Front Immunol. 2023 Jan 4;13:1071223. doi: 10.3389/fimmu.2022.1071223. eCollection 2022.
6
Evaluation of a Novel Oncolytic Adenovirus Silencing .新型溶瘤腺病毒沉默的评价
Int J Mol Sci. 2022 Dec 6;23(23):15430. doi: 10.3390/ijms232315430.
7
miRNA Pathway Alteration in Response to Non-Coding RNA Delivery in Viral Vector-Based Gene Therapy.miRNA 通路改变在病毒载体为基础的基因治疗中的非编码 RNA 递送上的反应。
Int J Mol Sci. 2022 Nov 29;23(23):14954. doi: 10.3390/ijms232314954.
8
An Adenoviral Vector as a Versatile Tool for Delivery and Expression of miRNAs.腺相关病毒载体作为一种通用的 miRNA 传递和表达工具。
Viruses. 2022 Sep 2;14(9):1952. doi: 10.3390/v14091952.
9
ErbB3-Targeting Oncolytic Adenovirus Causes Potent Tumor Suppression by Induction of Apoptosis in Cancer Cells.ErbB3 靶向溶瘤腺病毒通过诱导癌细胞凋亡引起强烈的肿瘤抑制作用。
Int J Mol Sci. 2022 Jun 27;23(13):7127. doi: 10.3390/ijms23137127.
10
Concepts in Oncolytic Adenovirus Therapy.溶瘤腺病毒治疗的概念。
Int J Mol Sci. 2021 Sep 29;22(19):10522. doi: 10.3390/ijms221910522.
生物选择揭示 miR-99b 和 miR-485 可增强胰腺癌细胞中的腺病毒溶瘤作用。
Mol Ther. 2019 Jan 2;27(1):230-243. doi: 10.1016/j.ymthe.2018.09.016. Epub 2018 Sep 27.
4
Regulation of microRNA biogenesis and its crosstalk with other cellular pathways.miRNA 生物发生的调控及其与其他细胞途径的串扰。
Nat Rev Mol Cell Biol. 2019 Jan;20(1):5-20. doi: 10.1038/s41580-018-0059-1.
5
Tumor suppressor miR-1 inhibits tumor growth and metastasis by simultaneously targeting multiple genes.肿瘤抑制性微小RNA-1通过同时靶向多个基因来抑制肿瘤生长和转移。
Oncotarget. 2017 Jun 27;8(26):42043-42060. doi: 10.18632/oncotarget.14927.
6
Functional Screening Identifies Human miRNAs that Modulate Adenovirus Propagation in Prostate Cancer Cells.功能筛选鉴定出调节前列腺癌细胞中腺病毒增殖的人类 miRNA。
Hum Gene Ther. 2017 Sep;28(9):766-780. doi: 10.1089/hum.2016.143. Epub 2017 Jan 23.
7
Re-evaluation of the roles of DROSHA, Export in 5, and DICER in microRNA biogenesis.对 Drosha、5' 端输出因子及 Dicer 在微小RNA生物合成中作用的重新评估。
Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1881-9. doi: 10.1073/pnas.1602532113. Epub 2016 Mar 14.
8
Oncolytic viruses: finally delivering.溶瘤病毒:终于开始发挥作用了。
Br J Cancer. 2016 Feb 16;114(4):357-61. doi: 10.1038/bjc.2015.481. Epub 2016 Jan 14.
9
Biochemical isolation of Argonaute protein complexes by Ago-APP.通过AGO-APP对Argonaute蛋白复合物进行生化分离。
Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):11841-5. doi: 10.1073/pnas.1506116112. Epub 2015 Sep 8.
10
Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells.全基因组慢病毒shRNA筛选确定富含丝氨酸/精氨酸的剪接因子2是乳腺癌细胞中溶瘤病毒活性的决定因素。
Oncogene. 2016 May 12;35(19):2465-74. doi: 10.1038/onc.2015.303. Epub 2015 Aug 10.